Becatecarin (Helsinn Healthcare).
Helsinn Healthcare SA is developing becatecarin, a topoisomerase II inhibitor for the potential intravenous treatment of cancer.
Rewcastle
Gordon W
GW
Auckland Cancer Society Research Center, Faculty of Medicine and Health Science, University of Auckland, New Zealand. g.rewcastle@auckland.ac.nz
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002227:Carbazoles / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004250:DNA Topoisomerases, Type II / Q000494:pharmacology / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D005960:Glucosides / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use*; D002955:Leucovorin / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013534:Survival; D059005:Topoisomerase II Inhibitors
D002227:Carbazoles; D005960:Glucosides; D007211:Indoles; D059005:Topoisomerase II Inhibitors; C093269:becatecarin; D004250:DNA Topoisomerases, Type II; D002955:Leucovorin; D005472:Fluorouracil